Changes

AA, Aplastic anemia; BMFS, Bone Marrow Failure Syndrome; MDS, Myelodysplastic Syndrome; MDS/MPN, Myelodysplastic/ myeloproliferative Neoplasm; MPN, Myeloproliferative Neoplasm; CML, Chronic Myelogeneous Leukemia; sAML, secondary AML; TGA, Total genomic aberration; TKI, tyrosine kinase inhibitors.  

AA, Aplastic anemia; BMFS, Bone Marrow Failure Syndrome; MDS, Myelodysplastic Syndrome; MDS/MPN, Myelodysplastic/ myeloproliferative Neoplasm; MPN, Myeloproliferative Neoplasm; CML, Chronic Myelogeneous Leukemia; sAML, secondary AML; TGA, Total genomic aberration; TKI, tyrosine kinase inhibitors.  

∗Recurrent indicates recurrent aberration with no established prognostic significance  

∗Recurrent indicates recurrent aberration with no established prognostic significance    

'''Table 2 -''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS Detected by CMA Testing (Literature Review).'''  Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.  

'''Table 2 -''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS Detected by CMA Testing (Literature Review).'''  Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.  

Legend: d- diagnostic significance; P-prognostic significance; T- therapeutic significance. Recurrent indicates recurrent aberration with no established prognostic significance.   

Legend: d- diagnostic significance; P-prognostic significance; T- therapeutic significance. Recurrent indicates recurrent aberration with no established prognostic significance.   

∗ Clinical significance based on WHO classification using IPSS-R (Greenberg et al., Blood 2012; Schanz et al., J Clin Oncol 2011).   

∗ Clinical significance based on WHO classification using IPSS-R<ref>{{Cite journal|last=Greenberg|first=Peter L.|last2=Tuechler|first2=Heinz|last3=Schanz|first3=Julie|last4=Sanz|first4=Guillermo|last5=Garcia-Manero|first5=Guillermo|last6=Solé|first6=Francesc|last7=Bennett|first7=John M.|last8=Bowen|first8=David|last9=Fenaux|first9=Pierre|date=2012|title=Revised international prognostic scoring system for myelodysplastic syndromes|url=https://www.ncbi.nlm.nih.gov/pubmed/22740453|journal=Blood|volume=120|issue=12|pages=2454–2465|doi=10.1182/blood-2012-03-420489|issn=1528-0020|pmc=4425443|pmid=22740453}}</ref><ref>{{Cite journal|last=Schanz|first=Julie|last2=Tüchler|first2=Heinz|last3=Solé|first3=Francesc|last4=Mallo|first4=Mar|last5=Luño|first5=Elisa|last6=Cervera|first6=José|last7=Granada|first7=Isabel|last8=Hildebrandt|first8=Barbara|last9=Slovak|first9=Marilyn L.|date=2012|title=New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge|url=https://www.ncbi.nlm.nih.gov/pubmed/22331955|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=30|issue=8|pages=820–829|doi=10.1200/JCO.2011.35.6394|issn=1527-7755|pmc=4874200|pmid=22331955}}</ref>.   

∗∗ Isolated trisomy 8 or del(20q) are not diagnostic of MDS in the absence of morphologic findings of disease.   

<nowiki>**</nowiki> Isolated trisomy 8 or del(20q) are not diagnostic of MDS in the absence of morphologic findings of disease.   

∗∗∗ Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors (Bejar et al., Blood 124:2705–12, 2014;Traina et al., Leukemia 28:78–87, 2014).   

∗∗∗ Potential marker for responsiveness to hypomethylating agents or DNA methyltransferase inhibitors<ref>{{Cite journal|last=Bejar|first=Rafael|last2=Lord|first2=Allegra|last3=Stevenson|first3=Kristen|last4=Bar-Natan|first4=Michal|last5=Pérez-Ladaga|first5=Albert|last6=Zaneveld|first6=Jacques|last7=Wang|first7=Hui|last8=Caughey|first8=Bennett|last9=Stojanov|first9=Petar|date=2014|title=TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients|url=https://www.ncbi.nlm.nih.gov/pubmed/25224413|journal=Blood|volume=124|issue=17|pages=2705–2712|doi=10.1182/blood-2014-06-582809|issn=1528-0020|pmc=4208285|pmid=25224413}}</ref><ref>{{Cite journal|last=Traina|first=F.|last2=Visconte|first2=V.|last3=Elson|first3=P.|last4=Tabarroki|first4=A.|last5=Jankowska|first5=A. M.|last6=Hasrouni|first6=E.|last7=Sugimoto|first7=Y.|last8=Szpurka|first8=H.|last9=Makishima|first9=H.|date=2014|title=Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms|url=https://www.ncbi.nlm.nih.gov/pubmed/24045501|journal=Leukemia|volume=28|issue=1|pages=78–87|doi=10.1038/leu.2013.269|issn=1476-5551|pmid=24045501}}</ref>.   

'''Table 3''' '''-''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS/MPN Detected by CMA Testing (Literature Review).'''  Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.  

'''Table 3''' '''-''' '''A Comprehensive List of Copy Number Aberrations and CN-LOH of Known or Likely Clinical Significance in MDS/MPN Detected by CMA Testing (Literature Review).'''  Table derived from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics.